

SECURITIES & EXCHANGE COMMISSION EDGAR FILING

PROVECTUS BIOPHARMACEUTICALS, INC.

Form: 4

Date Filed: 2017-01-09

Corporate Issuer CIK: 315545

© Copyright 2017, Issuer Direct Corporation. All Right Reserved. Distribution of this document is strictly prohibited, subject to the terms of use.

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number: Estimated average burden hours per response...

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

		Filed pur	suant to Sect	ion ro(a)	or the Securiti	es Excha	ange Act of 19	34 Or Se	ction 3	u(n) or the inve	estment Con	npany Ac	1011940						
Print or Type Responses)																			
I. Name and Address of Reporting Per CULPEPPER PETER R	rson_				Issuer Name and Ticker or Trading Symbol PROVECTUS BIOPHARMACEUTICALS, INC. [PVCT]							Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner							
P.O. BOX 32429	(First)		(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 12/28/2016								Officer (give title below) Prior Interim CEO, CFO, COO						
(NOXVILLE, TN 37930	(Street)			4. If A	4. If Amendment, Date Original FiledMonth/Day/Year)						X Forr	6. Individual or Joint/Group FillingCheck Applicable Line) X_Form field by One Reporting Person							
(City)	(State)		(Zip)						Table	e I - Non-Derivativ	ve Securities A	cquired, D	isposed of,	or Beneficially Owned					
I.Title of Security Instr. 3)				ansaction Day/Year			3. Transactio (Instr. 8)	on Code	(4. Securities Acqui (D) (Instr. 3, 4 and 5)	ired (A) or Dispo				Transaction(s)	otion(s) 6. 7. Ownership of Form: Be			
							Cod	Đ	v	Amount	(A) or (D)	Price					Direct (D) or Indirect (I) (Instr. 4)		
Common Stock												1,	,411,829				D		
Common Stock												29	96,503					By 401(k) plan	
Reminder: Report on a separate line fo	or each class of securiti	es beneficially owned di	rectly or indirectly	у.						espond to the col			ntained in th	is form are not required to res	spond unless the	form	SEC	1474 (9-02	
							Securities Acqu	ired, Disp	osed of	, or Beneficially (
I. Title of Derivative Security Instr. 3)	Conversion or Exercise Price of Derivative Security	Transaction Date (Month/Day/Year)	3A. Deemed E Date, if any (Month/Day/Ye	(Ir	. Transaction Code nstr. 8)	A	Number of Deriva cquired (A) or Disp nstr. 3, 4, and 5)			6. Date Exercis Expiration Date (Month/Day/Yea		7. Title an (Instr. 3 ar		Underlying Securities		9. Number of Derivative Securities	Ownership Form of	Beneficial	
					Code	v	(A)	(1	D)	Date Exercisable	Expiration Date	Title		Amount or Number of Shares	(Instr. 5)	Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Direct (D) or Indirect	Ownershi (Instr. 4)	
Share Option (Right to buy)	\$ 1									07/22/2010	07/22/2020	Comm	on Stock	550,000		550,000	D		
Share Option (Right to buy)	\$ 0.93									09/06/2011	09/06/2021		on Stock	550,000		550,000	D		
Share Ontion (Right to huv)	\$ n 75	·								12/09/2015	12/09/2025	Comm	on Stock	400.000		400 000	D		

03/29/2016 06/19/2020 Common Stock

266,666

Warrant (Right to buy) **Reporting Owners**

Daniel de Communitation (Address		Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other					
CULPEPPER PETER R									
P.O. BOX 32429				Prior Interim CEO, CFO, COO					
KNOXVILLE, TN 37930									

Signatures

/s/ Peter R. Culpepper	01/09/2017
-Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
 Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

On December 28, 2016, the reporting person, Peter Culpepper, was terminated as an officer and an interim officer of Provectus Biopharmaceuticals, Inc. (the "Issuer"). This Form 4 serves as his exit filing. No acquisitions, dispositions or other transactions involved

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per	
response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)																	
Name and Address of Reporting Person CULPEPPER PETER R					Issuer Name and Ticker or Trading Symbol PROVECTUS BIOPHARMACEUTICALS, INC. [PVCT]							5. Relationsh	Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
P.O. BOX 32429	(First)		(Middle)		Date of Earliest Transaction (Month/Day/Year) 12/28/2016						Officer (giv		X Other (speci				
(Street)					4. If Amendment, Date Original FiledMonth/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting Person				
KNOXVILLE, TN 37930												Form nied by	More than One Reporting Person				
(City)	(State)		(Zip)						Tab	le I - Non-Derivat	ive Securities A	cquired, Dispose	d of, or Beneficially Owned				
				ransaction Date nth/Day/Year)	Day/Year) Date, if any				n 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)				of 5. Amount of Securities Beneficially Owned Following Reported Transaction(s (Instr. 3 and 4)				7. Nature of Indirect Beneficial
							Cod	9	<	Amount	(A) or (D)	Price				Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
Common Stock											., .,	1,411,8	29			D	
Common Stock												296,50	3			ı	By 401(k) plan
Reminder: Report on a separate line for	or each class of securitie	es beneficially owned dir	ectly or indirect	tly.				displays	s a curi	rently valid OMB	control numbe		in this form are not required to re	spond unless the	e form	SEC	1474 (9-02)
							Securities Acqui			f, or Beneficially	Owned						
(Instr. 3) Exercise Price of (Month/Day/Year) Date, if any			Execution 4. Tra (Instr. 'ear)	nsaction Code	5. I Acı	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)			6. Date Exerci Expiration Dat (Month/Day/Y	е	7. Title and Amo (Instr. 3 and 4)	nt of Underlying Securities	8. Price of Derivative Security	Derivative Securities	Ownership Form of	Beneficial	
					Code	v	(A)	(0	D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	(Instr. 5)	Beneficially Owned Following Reported Transaction(s (Instr. 4)	Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
Share Option (Right to buy)	\$1									07/22/2010	07/22/2020	Common St	ock 550,000		550,000	D	
Share Option (Right to buy)	\$ 0.93									09/06/201	09/06/2021	Common St	ock 550,000		550,000	D	
Share Option (Right to buy)	\$ 0.75									12/09/2015	12/09/2025	Common St	ock 400,000		400,000	D	
Warrant (Right to buy)	\$ 0.85									03/29/2016	06/19/2020	Common St	ock 266,666		266,666	D	

Reporting Owners

		Relationships							
Reporting Owner Name / Address	Director	10% Owner	Owner Officer Other						
CULPEPPER PETER R									
P.O. BOX 32429				Prior Interim CEO, CFO, COO					
KNOXVILLE, TN 37930									

Signatures

/s/ Peter R. Culpepper	01/09/2017
-Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
 Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

On December 28, 2016, the reporting person, Peter Culpepper, was terminated as an officer and an interim officer of Provectus Biopharmaceuticals, Inc. (the "Issuer"). This Form 4 serves as his exit filing. No acquisitions, dispositions or other transactions involved the provided of the "Issuer".

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.